Journal of Clinical Oncology, Vol 11, 485-490, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

U Magriples, F Naftolin, PE Schwartz and ML Carcangiu
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510.

PURPOSE: Several reports have associated tamoxifen administration with endometrial carcinoma. A retrospective study of the histologic features of uterine cancer in patients with a history of breast carcinoma was undertaken to determine the effect of treatment with tamoxifen. MATERIALS AND METHODS: A computer search of the Yale-New Haven Hospital Tumor Registry from 1980 to 1990 identified 53 patients with a history of breast carcinoma who subsequently developed a malignant tumor of the uterine corpus. RESULTS: Fifteen patients received tamoxifen for breast carcinoma and 38 did not. The mean ages of the two groups were not significantly different. The mean interval between detection of breast and endometrial cancers was 5 years in the tamoxifen group and 12 years in the nontreated group (P = .0023). Sixty-seven percent of patients in the tamoxifen group had poorly differentiated endometrioid carcinomas (including adenosquamous carcinoma) or carcinomas associated with poor outcome (eg, uterine papillary serous carcinoma, clear-cell carcinoma, or mixed mullerian tumor), as compared with 24% in the nontreated group (P = .03). Patients in the tamoxifen group were much more likely to die of endometrial cancer (33.3% v 2.6% of the nontreated group, P = .005). CONCLUSION: From this retrospective study, it appears that women receiving tamoxifen as treatment for breast cancer who subsequently develop uterine cancer are at risk for high-grade endometrial cancers that have a poor prognosis. These findings also indicate that tamoxifen- associated uterine cancers may have a different basis from those associated with steroidal estrogen treatment.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, September 1, 2009; 24(5): 391 - 404. [Abstract] [Full Text] [PDF]

				V. C. Jordan The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death? J. Clin. Oncol., June 20, 2008; 26(18): 3073 - 3082. [Abstract] [Full Text] [PDF]

				W G McCluggage My approach to the interpretation of endometrial biopsies and curettings. J. Clin. Pathol., August 1, 2006; 59(8): 801 - 812. [Abstract] [Full Text] [PDF]

				B. Gerber, A. Krause, T. Reimer, I. Mylonas, J. Makovitzky, G. Kundt, and W. Janni Anastrozole versus Tamoxifen Treatment in Postmenopausal Women with Endocrine-Responsive Breast Cancer and Tamoxifen-Induced Endometrial Pathology Clin. Cancer Res., February 15, 2006; 12(4): 1245 - 1250. [Abstract] [Full Text] [PDF]

				B. Fisher, J. P. Costantino, D. L. Wickerham, R. S. Cecchini, W. M. Cronin, A. Robidoux, T. B. Bevers, M. T. Kavanah, J. N. Atkins, R. G. Margolese, et al. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst, November 16, 2005; 97(22): 1652 - 1662. [Abstract] [Full Text] [PDF]

				H. Hung Suppression of ps20 Expression in the Rat Uterus by Tamoxifen and Estrogens Endocrinology, May 1, 2005; 146(5): 2388 - 2396. [Abstract] [Full Text] [PDF]

				E. Sivridis and A. Giatromanolaki Endometrial Adenocarcinoma: Beliefs and Scepticism International Journal of Surgical Pathology, April 1, 2004; 12(2): 99 - 105. [Abstract] [PDF]

				V. C. Jordan and M. Morrow Re: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999 J Natl Cancer Inst, May 7, 2003; 95(9): 683 - 684. [Full Text] [PDF]

				R. J Cersosimo Tamoxifen for Prevention of Breast Cancer Ann. Pharmacother., February 1, 2003; 37(2): 268 - 273. [Abstract] [Full Text] [PDF]

				N. F. Col, R. J. Goldberg, R. K. Orr, J. K. Erban, J. M. Fortin, and R. T. Chlebowski Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model Med Decis Making, October 1, 2002; 22(5): 386 - 393. [Abstract] [PDF]

				H. Huynh, C. Y. Ng, K. B. Lim, C. K. Ong, C. S. Ong, E. Tran, T. T. Tuyen Nguyen, and T. W. M. G. Chan Induction of UO-44 Gene Expression by Tamoxifen in the Rat Uterus and Ovary Endocrinology, July 1, 2001; 142(7): 2985 - 2995. [Abstract] [Full Text] [PDF]

				R. R. Barakat, T. A. Gilewski, L. Almadrones, P. E. Saigo, E. Venkatraman, C. Hudis, and W. J. Hoskins Effect of Adjuvant Tamoxifen on the Endometrium in Women With Breast Cancer: A Prospective Study Using Office Endometrial Biopsy J. Clin. Oncol., October 20, 2000; 18(20): 3459 - 3463. [Abstract] [Full Text] [PDF]

				B. Gerber, A. Krause, H. Muller, T. Reimer, T. Kulz, J. Makovitzky, G. Kundt, and K. Friese Effects of Adjuvant Tamoxifen on the Endometrium in Postmenopausal Women With Breast Cancer: A Prospective Long-Term Study Using Transvaginal Ultrasound J. Clin. Oncol., October 20, 2000; 18(20): 3464 - 3470. [Abstract] [Full Text] [PDF]

				S. M. Ascher, I. Imaoka, and J. M. Lage Tamoxifen-induced Uterine Abnormalities: The Role of Imaging1 Radiology, January 1, 2000; 214(1): 29 - 38. [Abstract] [Full Text]

				E. J. Suh-Burgmann and A. Goodman Surveillance for Endometrial Cancer in Women Receiving Tamoxifen Ann Intern Med, July 20, 1999; 131(2): 127 - 135. [Abstract] [Full Text] [PDF]

				M. W. DeGregorio, R. O'Regan, and V. C. Jordan Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth • RESPONSE J Natl Cancer Inst, March 3, 1999; 91(5): 474 - 475. [Full Text] [PDF]

				F. A. Beland, L. P. McDaniel, and M. M. Marques Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo Carcinogenesis, March 1, 1999; 20(3): 471 - 477. [Abstract] [Full Text] [PDF]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				K. Yao and V. C. Jordan Questions about Tamoxifen and the Future Use of Antiestrogens Oncologist, April 1, 1998; 3(2): 104 - 110. [Abstract] [Full Text]

				C. A. Hudis and L. Norton Adjuvant Drug Treatment for Resectable Breast Cancer Oncologist, December 1, 1997; 2(6): 351 - 358. [Abstract] [Full Text] [PDF]